Tag: pricing

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

Issued on behalf of Greenland Mines Ltd.Greenland Mines Ltd. (Nasdaq: GRML) has signed a diamond drilling contract with Arctic specialist Nordisk Fundering for a...

Leading independent Technology Solutions Distributor Sandler Partners adds Connectivity pricing to SCOUT email, helping Partners look up Connectivity options and quote solutions for clients...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- The global Content Delivery Network (CDN) Market is projected to grow from USD 18.84 billion in 2026 to USD...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- The global Content Delivery Network (CDN) Market is projected to grow from USD 18.84 billion in 2026 to USD...

After two decades as a cloud communications provider, the Buffalo company is turning everyday calls and messages using AI into private, secure intelligence, built on infrastructure it controls, with a simple promise: your data stays yours.

After two decades as a cloud communications provider, the Buffalo company is turning everyday calls and messages using AI into private, secure intelligence, built on infrastructure it controls, with a simple promise: your data stays yours.

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Native video, custom audience targeting, and real-time optimization helped GUESS FRAGRANCES beat engagement benchmarks during one of advertising's most competitive momentsCANNES, France, June 25,...

BEIJING, June 25, 2026 /PRNewswire/ -- On June 23, two indices gauging prices of yak and Tibetan sheep in northwest China's Qinghai Province were released...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

RALEIGH, N.C., June 24, 2026 /PRNewswire/ -- Cardinal Infrastructure Group, Inc. (the "Company" or "Cardinal") (Nasdaq: CDNL) today announced the pricing of an upsized...